Department of Emergency Medicine, Naval Medical Center San Diego, 34800 Bob Wilson Drive, San Diego, CA 92134, United States of America.
Department of Emergency Medicine, Naval Medical Center San Diego, 34800 Bob Wilson Drive, San Diego, CA 92134, United States of America.
Am J Emerg Med. 2024 Jun;80:138-142. doi: 10.1016/j.ajem.2024.03.025. Epub 2024 Mar 24.
Fever following immunizations is a common presenting chiefcomplaint among infants. The 2021 American Academy of Pediatrics (AAP) febrile infant clinical practice guidelines exclude recently immunized (RI) infants. This is a challenge for clinicians in the management of the febrile RI young infant. The objective of this study was to assess the prevalence of SBI in RI febrile young infants between 6 and 12 weeks of age.
This was a retrospective chart review of infants 6-12 weeks who presented with a fever ≥38 °C to two U.S. military academic Emergency Departments over a four-year period. Infants were considered recently immunized (RI) if they had received immunizations in the preceding 72 h prior to evaluation and not recently immunized (NRI) if they had not received immunizations during this time period. The primary outcome was prevalence of serious bacterial infection (SBI) further delineated into invasive-bacterial infection (IBI) and non-invasive bacterial infection (non-IBI) based on culture and/or radiograph reports.
Of the 508 febrile infants identified, 114 had received recent immunizations in the preceding 72 h. The overall prevalence of SBI was 11.4% (95% CI = 8.9-14.6) in our study population. The prevalence of SBI in NRI infants was 13.7% (95% CI = 10.6-17.6) compared to 3.5% (95% CI = 1.1-9.3) in RI infants. The relative risk of SBI in the setting of recent immunizations was 0.3 (95% CI = 0.1-0.7). There were no cases of invasive-bacterial infections (IBI) in the RI group with all but one of the SBI being urinary tract infections (UTI). The single non-UTI was a case of pneumonia in an infant who presented with respiratory symptoms within 24 h of immunizations.
The risk of IBI (meningitis or bacteremia) in RI infants aged 6 to 12 weeks is low. Non-IBI within the first 24 h following immunization was significantly lower than in febrile NRI infants. UTIs remain a risk in the RI population and investigation with urinalysis and urine culture should be encouraged. Shared decision making with families guide a less invasive approach to the care of these children. Future research utilizing a large prospective multi-center data registry would aid in further defining the risk of both IBI and non-IBI among RI infants.
疫苗接种后发热是婴儿常见的主要主诉之一。2021 年美国儿科学会(AAP)发热婴儿临床实践指南排除了最近接种疫苗(RI)的婴儿。这对发热 RI 婴儿的临床医生的管理提出了挑战。本研究的目的是评估 6-12 周龄 RI 发热婴儿中 SBI 的患病率。
这是对两家美国军事学术急诊部门在四年期间因发热≥38°C 就诊的 6-12 周龄婴儿进行的回顾性图表审查。如果婴儿在评估前的 72 小时内接受了免疫接种,则认为其最近接受了免疫接种(RI),如果在此期间未接受免疫接种,则认为其最近未接受免疫接种(NRI)。主要结局是严重细菌感染(SBI)的患病率,进一步根据培养和/或放射报告细分为侵袭性细菌感染(IBI)和非侵袭性细菌感染(非 IBI)。
在 508 名发热婴儿中,有 114 名在过去 72 小时内接受了最近的免疫接种。在我们的研究人群中,SBI 的总体患病率为 11.4%(95%CI=8.9-14.6)。NRI 婴儿的 SBI 患病率为 13.7%(95%CI=10.6-17.6),而 RI 婴儿为 3.5%(95%CI=1.1-9.3)。最近免疫接种时 SBI 的相对风险为 0.3(95%CI=0.1-0.7)。RI 组无侵袭性细菌感染(IBI)病例,所有 SBI 均为尿路感染(UTI),除一例外。唯一的非 UTI 是一名婴儿在免疫接种后 24 小时内出现呼吸道症状的肺炎病例。
6-12 周龄 RI 婴儿发生 IBI(脑膜炎或菌血症)的风险较低。免疫接种后 24 小时内出现非 IBI 的风险明显低于发热 NRI 婴儿。UTI 仍然是 RI 人群的风险,应鼓励进行尿液分析和尿液培养检查。与家庭共同决策指导这些儿童的治疗采用侵入性较小的方法。利用大型前瞻性多中心数据登记处进行的未来研究将有助于进一步确定 RI 婴儿中 IBI 和非 IBI 的风险。